Precipio Inc (TBIO):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Precipio Inc (TBIO) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7329
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Precipio Inc (Precipio), formerly Transgenomic Inc, is a developer and provider of diagnostic tools and services. The company advances personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. It offers ICEme Kits, which finds applications for mutation specific, disease specific and gene specific panels. Precipio uses ICE COLD-PCR, a sensitivity platform technology, which enables adoption of personalized, precision medicine in cancer and other diseases. Transgenomic’S MX-ICP is an amplification technology that suppresses normal DNA and thereby enables the selective amplification of mutations. Its MX-ICP works on sample types that contain DNA, including tissue, blood, urine and saliva or sputum. It operates through its research and development facility located in Omaha, Nebraska, the US. Precipio is headquartered in Omaha, Nebraska, the US.

Precipio Inc (TBIO) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Precipio Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Precipio Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Precipio Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Precipio Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Precipio Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Precipio Inc, Medical Equipment, Deal Details 11
Asset Purchase 11
Transgenomic Completes Acquisition Of Rights To Scoliscore AIS Prognostic Test From Axial Biotech For US$4 Million 11
Partnerships 13
LifeLabs Enters into Licensing Agreement with Transgenomic 13
University of Melbourne Enters into Licensing Agreement with Transgenomic 14
Transgenomic Expands Licensing Agreement with Dana-Farber Cancer Institute for Multiplexed Ice cold-PCR Technlogy 15
Quest Diagnostics Enters Into Licensing Agreement With Transgenomic For Opioid Therapy Genetic Test 16
Precipio Enters into Agreement with Nucleai 17
Transgenomic Enters Into Co-Development Agreement With Horizon Diagnostics For Genetic Diagnostic Tests 18
Transgenomic Enters Into Co-Marketing Agreement With PerkinElmer For Oncology Diagnostic Test Portfolio 19
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 20
Transgenomic Expands Licensing Agreement with Exiqon 21
Equity Offering 22
Transgenomic Raises USD1.2 Million in First Tranche of Private Placement of Shares 22
Transgenomic to Raise up to USD3.5 Million in Public Offering of Shares 24
Transgenomic Raises up to USD2.2 Million in Private Placement of Preferred Stock and Warrant 25
Transgenomic Raises USD7 Million in Public Offering of Shares and Warrants 26
Transgenomic Raises USD7 Million in Private Placement of Shares 28
Transgenomic Completes Private Placement Of Shares For USD8.3 Million 29
Transgenomic Completes Private Placement Of Shares For US$19 Million 30
Debt Offering 31
Transgenomic Raises USD1.2 Million in Private Placement 31
Transgenomic Raises USD0.9 Million in Priavte Placement of Promissory Notes 32
Asset Transactions 33
ADSTEC Acquires Genetic Assays & Platforms Business Unit from Transgenomic 33
Edge Biosystems Acquires Ion Chromatography Product Line and Related Assets from Transgenomic for USD2 Million 34
Integrated DNA Technologies Acquires Rights to Surveyor Mutation Detection Technology and Assets from Transgenomic for up to USD4.25 Million 35
Acquisition 36
Transgenomic Acquires Precipio Diagnostics 36
Precipio Inc – Key Competitors 37
Precipio Inc – Key Employees 38
Precipio Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Jul 18, 2018: Precipio announces 213% year-over-year revenue growth in preliminary Q2-2018 results 40
Corporate Communications 41
Aug 09, 2018: Precipio Appoints New Board Member to Replace Departing Director 41
Legal and Regulatory 42
Mar 13, 2018: Precipio Settles Lawsuit with Crede Capital 42
Government and Public Interest 43
Apr 03, 2018: Important JAMA Article Underscores Superiority of Precipio’s Liquid Biopsy Core Technology 43
Product News 45
Mar 20, 2018: Precipio Integrates Cost Reducing and Fast Turnaround “High Resolution Melt” into Liquid Biopsy Platform 45
Jun 13, 2017: European Patent Office Confirms Grant of New ICE COLD-PCR Patent Exclusively Licensed to Transgenomic 47
Other Significant Developments 48
Apr 11, 2018: Precipio Launches ICE COLD-PCR Research Access Program for Cancer Centers 48
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Precipio Inc, Medical Equipment, Key Facts, 2017 2
Precipio Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Precipio Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Precipio Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Precipio Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Precipio Inc, Deals By Market, 2012 to YTD 2018 9
Precipio Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Transgenomic Completes Acquisition Of Rights To Scoliscore AIS Prognostic Test From Axial Biotech For US$4 Million 11
LifeLabs Enters into Licensing Agreement with Transgenomic 13
University of Melbourne Enters into Licensing Agreement with Transgenomic 14
Transgenomic Expands Licensing Agreement with Dana-Farber Cancer Institute for Multiplexed Ice cold-PCR Technlogy 15
Quest Diagnostics Enters Into Licensing Agreement With Transgenomic For Opioid Therapy Genetic Test 16
Precipio Enters into Agreement with Nucleai 17
Transgenomic Enters Into Co-Development Agreement With Horizon Diagnostics For Genetic Diagnostic Tests 18
Transgenomic Enters Into Co-Marketing Agreement With PerkinElmer For Oncology Diagnostic Test Portfolio 19
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 20
Transgenomic Expands Licensing Agreement with Exiqon 21
Transgenomic Raises USD1.2 Million in First Tranche of Private Placement of Shares 22
Transgenomic to Raise up to USD3.5 Million in Public Offering of Shares 24
Transgenomic Raises up to USD2.2 Million in Private Placement of Preferred Stock and Warrant 25
Transgenomic Raises USD7 Million in Public Offering of Shares and Warrants 26
Transgenomic Raises USD7 Million in Private Placement of Shares 28
Transgenomic Completes Private Placement Of Shares For USD8.3 Million 29
Transgenomic Completes Private Placement Of Shares For US$19 Million 30
Transgenomic Raises USD1.2 Million in Private Placement 31
Transgenomic Raises USD0.9 Million in Priavte Placement of Promissory Notes 32
ADSTEC Acquires Genetic Assays & Platforms Business Unit from Transgenomic 33
Edge Biosystems Acquires Ion Chromatography Product Line and Related Assets from Transgenomic for USD2 Million 34
Integrated DNA Technologies Acquires Rights to Surveyor Mutation Detection Technology and Assets from Transgenomic for up to USD4.25 Million 35
Transgenomic Acquires Precipio Diagnostics 36
Precipio Inc, Key Competitors 37
Precipio Inc, Key Employees 38
Precipio Inc, Other Locations 39
Precipio Inc, Subsidiaries 39

List of Figures
Precipio Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Precipio Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Precipio Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Precipio Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Precipio Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Precipio Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Precipio Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Precipio Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Precipio Inc (TBIO):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Whataburger Restaurants LP:戦略・SWOT・企業財務分析
    Whataburger Restaurants LP - Strategy, SWOT and Corporate Finance Report Summary Whataburger Restaurants LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Italiaonline S.p.A. (IOL):企業の財務・戦略的SWOT分析
    Italiaonline S.p.A. (IOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Royal DSM NV (DSM):企業の財務・戦略的SWOT分析
    Royal DSM NV (DSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • GVC Holdings PLC:戦略・SWOT・企業財務分析
    GVC Holdings PLC - Strategy, SWOT and Corporate Finance Report Summary GVC Holdings PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Eddie Bauer LLC:企業の戦略的SWOT分析
    Eddie Bauer LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Ildong Pharmaceutical Co Ltd (000230):企業の財務・戦略的SWOT分析
    Summary Ildong Pharmaceutical Co Ltd (IPC) is a manufacturer of pharmaceutical products. The company offers finished drugs, health foods and foods, raw material drugs, cosmetics and medical devices and others. Its raw material drugs comprise synthesis, probiotics, vitamins and biometabolites. IPC al …
  • Nobilis Health Corp (NHC):企業の財務・戦略的SWOT分析
    Summary Nobilis Health Corp (Nobilis Health), formerly Northstar Healthcare Inc is a healthcare development and management company that offers outpatient surgery and healthcare solutions. The center’s services include surgical services, surgery and critical patient education services. Its surgical s …
  • DHL Supply Chain (formerly Exel Inc.):戦略・SWOT・企業財務分析
    DHL Supply Chain (formerly Exel Inc.) - Strategy, SWOT and Corporate Finance Report Summary DHL Supply Chain (formerly Exel Inc.) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Newalta Corp (NAL):石油・ガス:M&Aディール及び事業提携情報
    Summary Newalta Corp (Newalta) is a provider of sustainability-enhancing solutions to the oil and gas industry. It adopts technologies to maximize the value inherent in oil and gas exploration and production waste streams. The company provides engineered environmental solutions for waste management …
  • Alacer Gold Corp:企業の戦略・SWOT・財務分析
    Alacer Gold Corp - Strategy, SWOT and Corporate Finance Report Summary Alacer Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Xbrane Biopharma AB (XBRANE):企業の財務・戦略的SWOT分析
    Summary Xbrane Biopharma AB (Xbrane), formerly Xbrane Bioscience AB is a biopharmaceutical company that develops and manufactures complex generic products . The company's product portfolio includes biosimilars and long acting injectables developed for people suffering from critical diseases. It comb …
  • SFS Group AG:企業の戦略・SWOT・財務情報
    SFS Group AG - Strategy, SWOT and Corporate Finance Report Summary SFS Group AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Byotrol Plc (BYOT):企業の財務・戦略的SWOT分析
    Summary Byotrol Plc (Byotrol) is a developer of residual antimicrobial technologies. The company offers multi pet surface disinfectant, advance moisture shampoo, advanced moisture, conditioning spray, advanced stain and odour, every day odour control spray, among others. It also identifies, develops …
  • Cathedral Energy Services Ltd (CET):企業の財務・戦略的SWOT分析
    Summary Cathedral Energy Services Ltd (Cathedral) is an oil and gas company that provides drilling and completion services. The company's services include horizontal and directional drilling services, flowback and production testing, production testing services, measurement while drilling services a …
  • Civica Group Limited:企業の戦略的SWOT分析
    Civica Group Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Calpine Corporation:戦略・SWOT・企業財務分析
    Calpine Corporation - Strategy, SWOT and Corporate Finance Report Summary Calpine Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Firalis SAS:企業の製品パイプライン分析2018
    Summary Firalis SAS (Firalis) is a biotechnology company that develops biomarkers and biomarker-based diagnostic kits. The company’s biomarker products comprise recombinant proteins and calibrants, Elisa kits, and monoclonal antibodies, among others. It offers biomarker services such as flow cytomet …
  • Northern Power Systems Corp (NPS):企業の財務・戦略的SWOT分析
    Summary Northern Power Systems Corp (NPS), formerly Mira III Acquisition Corp is a renewable energy company that offers engineering solutions to energy sector. The company's products comprise wind turbines, power converters, microgrids, power technology products and others. It offers services such a …
  • Saturn NPO:企業の戦略・SWOT・財務情報
    Saturn NPO - Strategy, SWOT and Corporate Finance Report Summary Saturn NPO - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • NOWDiagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary NOWDiagnostics Inc (NOWDiagnostics) is a medical diagnostic company. The company manufactures and sells blood-based rapid tests. It offers acetaminophen test, hCG test, H-FABP test, methanol dip test, salicylate test, troponin I test, myoglobin test, in home HIV test, and others. NOWDiagnost …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆